Outcomes of macular neovascularization treated with intravitreal injection of Aflibercept with Treat and extend

Outcomes of macular neovascularization treated with intravitreal injection of Aflibercept with Treat and extend - AMD treated by anti-VEGF drugs

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040311

Enrollment

Registered

2020-05-05

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AMD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have been previously treated with photodynamic therapy or anti-VEGF drug with Pro re Nata for Age-related Macular Degeneration, and underwent intravitreal injection with Aflibercept for age-related macular degeneration from January 2013 to April 2016.

Exclusion criteria

Exclusion criteria: Patients with a history of vitreous surgery or glaucoma surgery.

Design outcomes

Primary

Measure	Time frame
Gender, age, visual acuity, past history, fundus photograph, optical coherence tomography, fluorescein fundus, number of dosing, dosing interval	—

Countries

Japan

Contacts

Public ContactKeiko Kataoka

Nagoya University Hospital Department of Ophthalmology

kkeiko@med.nagoya-u.ac.jp052-741-2111

Outcome results